Jianping Mao1, Wenliang Gao2, Lianguo Xue1, Lidong Zhao1, Lei Miao1, Tao Jia1, Yuanxin Zhu1, Ying Wang1, Lijuan Meng3, Juan Wang4. 1. Department of Hematology, The First People's Hospital of Lianyungang City, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang Clinical College of Nanjing Medical University Lianyungang, China. 2. Department of Internal Medicine, The Second Children and Women's Health Care of Jinan City Jinan, China. 3. Department of Geriatric Oncology, The First Affiliated Hospital with Nanjing Medical University Nanjing, China. 4. Department of Pediatrics, The First People's Hospital of Lianyungang City Lianyungang, China.
Abstract
BACKGROUND AND OBJECTIVE: Acute myeloid leukemia (AML) is the most common form of hematological malignancy in adults. We aimed to investigate the efficacy of different treatment measures and prognostic factors for elderly patients with AML. METHODS: The clinical data of 65 newly diagnosed elderly patients with AML were retrospectively analyzed. Among them, 45 patients received induction chemotherapy including standard cytarabine regimen (n = 21) and low dose cytarabine regimen (n = 24), and 20 patients received palliative treatment. The efficacy and prognosis were compared between the groups. RESULTS: There were no statistical differences in complete remission, overall survival and the 6-month disease-free survival rates between standard cytarabine group and low dose cytarabine group (P = 0.675, P = 0.775, P = 0.751, respectively). Significant difference in median overall survival and overall survival rate were detected (P < 0.001, P = 0.031, respectively), but no significant difference in early death rate (P = 0.238) was found between induction chemotherapy group and palliative treatment group. Multivariate analysis showed that the white blood cells count ≥ 100.0 × 109/L was associated with early death. CONCLUSIONS: The induction chemotherapy did not increase the early mortality. The low dose cytarabine regimen can be used as the first-line choice for elderly acute myeloid leukemia patients who are not suitable for intensive chemotherapy. AJBR
BACKGROUND AND OBJECTIVE:Acute myeloid leukemia (AML) is the most common form of hematological malignancy in adults. We aimed to investigate the efficacy of different treatment measures and prognostic factors for elderly patients with AML. METHODS: The clinical data of 65 newly diagnosed elderly patients with AML were retrospectively analyzed. Among them, 45 patients received induction chemotherapy including standard cytarabine regimen (n = 21) and low dose cytarabine regimen (n = 24), and 20 patients received palliative treatment. The efficacy and prognosis were compared between the groups. RESULTS: There were no statistical differences in complete remission, overall survival and the 6-month disease-free survival rates between standard cytarabine group and low dose cytarabine group (P = 0.675, P = 0.775, P = 0.751, respectively). Significant difference in median overall survival and overall survival rate were detected (P < 0.001, P = 0.031, respectively), but no significant difference in early death rate (P = 0.238) was found between induction chemotherapy group and palliative treatment group. Multivariate analysis showed that the white blood cells count ≥ 100.0 × 109/L was associated with early death. CONCLUSIONS: The induction chemotherapy did not increase the early mortality. The low dose cytarabine regimen can be used as the first-line choice for elderly acute myeloid leukemiapatients who are not suitable for intensive chemotherapy. AJBR
Authors: G Juliusson; R Billström; A Gruber; E Hellström-Lindberg; M Höglunds; K Karlsson; D Stockelberg; A Wahlin; M Aström; C Arnesson; U Brunell-Abrahamsson; J Carstensen; E Fredriksson; E Holmberg; K Nordenskjöld; F Wiklund Journal: Leukemia Date: 2006-01 Impact factor: 11.528
Authors: James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield Journal: Blood Date: 2009-04-08 Impact factor: 22.113
Authors: Gunnar Juliusson; Petar Antunovic; Asa Derolf; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Ulf Tidefelt; Anders Wahlin; Martin Höglund Journal: Blood Date: 2008-11-13 Impact factor: 22.113